Template:Demyelinating diseases of CNS: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
en>Whywhenwhohow add Ocrelizumab/hyaluronidase |
||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| name = Demyelinating diseases of CNS | | name = Demyelinating diseases of CNS | ||
| title = | | title = Demyelinating diseases of the [[central nervous system]] | ||
| state = {{{state|}}} | | state = {{{state|}}} | ||
| bodyclass = hlist | | bodyclass = hlist | ||
| group1 = [[ | | group1 = [[Signs and symptoms of multiple sclerosis|Signs and symptoms]] | ||
| list1 = | | list1 = | ||
* [[Ataxia]] | * [[Ataxia]] | ||
| Line 21: | Line 21: | ||
| group2 = Investigations and diagnosis | | group2 = Investigations and diagnosis | ||
| list2 = | | list2 = | ||
* [[ | * [[Diagnosis of multiple sclerosis]] | ||
** [[McDonald criteria]] | ** [[McDonald criteria]] | ||
* [[Poser criteria]] | * [[Poser criteria]] | ||
| Line 34: | Line 34: | ||
** [[Lesional demyelinations of the central nervous system]] | ** [[Lesional demyelinations of the central nervous system]] | ||
** [[Dawson's fingers]] | ** [[Dawson's fingers]] | ||
* [[Frexalimab]] | |||
| group4 = Approved | | group4 = Approved treatment | ||
| list4 = | | list4 = | ||
* [[Management of multiple sclerosis]] | * [[Management of multiple sclerosis]] | ||
| Line 41: | Line 42: | ||
* [[Cladribine]] | * [[Cladribine]] | ||
* [[Dimethyl fumarate]] | * [[Dimethyl fumarate]] | ||
* [[Diroximel fumarate]] | |||
* [[Fingolimod]] | * [[Fingolimod]] | ||
* [[Glatiramer acetate]] | * [[Glatiramer acetate]] | ||
* [[Interferon beta-1a]] | * [[Interferon beta-1a]] | ||
* [[Interferon beta-1b]] | * [[Interferon beta-1b]] | ||
* [[Laquinimod]] | |||
* [[Mitoxantrone]] | * [[Mitoxantrone]] | ||
* [[Monomethyl fumarate]] | |||
* [[Natalizumab]] | * [[Natalizumab]] | ||
* [[Ocrelizumab]] | * [[Ocrelizumab]] ([[Ocrelizumab/hyaluronidase|+hyaluronidase]]) | ||
* [[Ozanimod]] | * [[Ozanimod]] | ||
* [[Ponesimod]] | |||
* [[Siponimod]] | * [[Siponimod]] | ||
* [[Teriflunomide]] | * [[Teriflunomide]] | ||
| Line 56: | Line 61: | ||
* Former | * Former | ||
** [[Daclizumab]] | ** [[Daclizumab]] | ||
* [[ | * [[Research in multiple sclerosis]] | ||
| group6 = | | group6 = Demyelinating diseases | ||
| list6 = {{Navbox|subgroup | | list6 = {{Navbox|subgroup | ||
| | | group2 = [[CNS demyelinating autoimmune diseases|Autoimmune]] | ||
| | | list2 = | ||
* [[Neuromyelitis optica spectrum disorder]] | |||
* [[Diffuse myelinoclastic sclerosis]] | |||
* [[MOG antibody disease]] | |||
* [[Multiple sclerosis]] | * [[Multiple sclerosis]] | ||
* [[ | * [[Chronic inflammatory demyelinating polyneuropathy]] | ||
| | | group3 = [[Inflammatory demyelinating diseases of the central nervous system|Inflammatory]] | ||
| | | list3 = | ||
* [[Acute disseminated encephalomyelitis]] | * [[Acute disseminated encephalomyelitis]] | ||
* [[Balo concentric sclerosis]] | * [[Balo concentric sclerosis]] | ||
* [[Marburg acute multiple sclerosis]] | * [[Marburg acute multiple sclerosis]] | ||
* [[Neuromyelitis optica]] | * [[Neuromyelitis optica spectrum disorder]] | ||
* [[Diffuse myelinoclastic sclerosis]] | * [[Diffuse myelinoclastic sclerosis]] | ||
* [[Tumefactive multiple sclerosis]] | * [[Tumefactive multiple sclerosis]] | ||
* [[Experimental autoimmune encephalomyelitis]] | * [[Experimental autoimmune encephalomyelitis]] | ||
| | | group4 = [[Hereditary CNS demyelinating disease|Hereditary]] | ||
| | | list4 = | ||
* [[Adrenoleukodystrophy]] | * [[Adrenoleukodystrophy]] | ||
* [[Alexander disease]] | * [[Alexander disease]] | ||
| Line 90: | Line 96: | ||
* [[CAMFAK syndrome]] | * [[CAMFAK syndrome]] | ||
| | | group5 = Other | ||
| | | list5 = | ||
* [[Central pontine myelinolysis]] | * [[Central pontine myelinolysis]] | ||
* [[Marchiafava–Bignami disease]] | * [[Marchiafava–Bignami disease]] | ||
| Line 105: | Line 111: | ||
}}<noinclude> | }}<noinclude> | ||
{{collapsible option}} | {{collapsible option}} | ||
[[Category: | [[Category:Neurological disorders templates]] | ||
</noinclude> | </noinclude> | ||
Revision as of 23:24, 13 September 2024
| Demyelinating diseases of the central nervous system | ||||||||
|---|---|---|---|---|---|---|---|---|
|
